Literature DB >> 27856683

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Frederick S Barrett1, Matthew P Bradstreet2, Jeannie-Marie S Leoutsakos2, Matthew W Johnson2, Roland R Griffiths2,3.   

Abstract

Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.
© The Author(s) 2016.

Entities:  

Keywords:  Psilocybin; challenging experiences; factor analysis; psychedelics; scale development

Mesh:

Substances:

Year:  2016        PMID: 27856683      PMCID: PMC5549781          DOI: 10.1177/0269881116678781

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  53 in total

1.  Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.

Authors:  J Riba; A Rodríguez-Fornells; G Urbano; A Morte; R Antonijoan; M Montero; J C Callaway; M J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

2.  Lysergic acid diethylamide (LSD-25). XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts.

Authors:  H A ABRAMSON
Journal:  J Ment Sci       Date:  1960-07

3.  MMPI score changes induced by lysergic acid diethylamide (LSD-25).

Authors:  R E BELLEVILLE
Journal:  J Clin Psychol       Date:  1956-07

4.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

5.  Psychedelics not linked to mental health problems or suicidal behavior: a population study.

Authors:  Pål-Ørjan Johansen; Teri Suzanne Krebs
Journal:  J Psychopharmacol       Date:  2015-03-05       Impact factor: 4.153

6.  LSD-assisted psychotherapy with terminal cancer patients.

Authors:  W N Pahnke; A A Kurland; L E Goodman; W A Richards
Journal:  Curr Psychiatr Ther       Date:  1969

7.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

8.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

9.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

10.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

View more
  55 in total

1.  The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Authors:  Alan K Davis; Joseph P Barsuglia; Rafael Lancelotta; Robert M Grant; Elise Renn
Journal:  J Psychopharmacol       Date:  2018-04-30       Impact factor: 4.153

2.  High dose psilocybin is associated with positive subjective effects in healthy volunteers.

Authors:  Christopher R Nicholas; Kelsey M Henriquez; Michele C Gassman; Karen M Cooper; Daniel Muller; Scott Hetzel; Randall T Brown; Nicholas V Cozzi; Chantelle Thomas; Paul R Hutson
Journal:  J Psychopharmacol       Date:  2018-06-27       Impact factor: 4.153

3.  Neuroticism is associated with challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  Pers Individ Dif       Date:  2017-06-07

4.  Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.

Authors:  Alan K Davis; Frederick S Barrett; Roland R Griffiths
Journal:  J Contextual Behav Sci       Date:  2019-11-16

5.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Authors:  Theresa M Carbonaro; Matthew W Johnson; Ethan Hurwitz; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2017-11-07       Impact factor: 4.530

6.  Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.

Authors:  Rafael L Lancelotta; Alan K Davis
Journal:  J Psychoactive Drugs       Date:  2020-03-09

7.  Replication and extension of a model predicting response to psilocybin.

Authors:  Suzanne L Russ; R L Carhart-Harris; G Maruyama; M S Elliott
Journal:  Psychopharmacology (Berl)       Date:  2019-06-15       Impact factor: 4.530

8.  Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy.

Authors:  Justin C Strickland; Albert Garcia-Romeu; Matthew W Johnson
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-29

9.  Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes.

Authors:  Gabrielle Agin-Liebes; Trevor F Haas; Rafael Lancelotta; Malin V Uthaug; Johannes G Ramaekers; Alan K Davis
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-23

Review 10.  Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.

Authors:  Jake E Payne; Richard Chambers; Paul Liknaitzky
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.